Lv11
80 积分 2021-07-24 加入
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
2天前
已完结
Targeting Solid Tumors Using CD3 Bispecific Antibodies
1个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
2个月前
已完结
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
2个月前
已完结
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
3个月前
已完结
Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms
3个月前
已完结
Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial
5个月前
已完结
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
5个月前
已完结
Diagnosis and Treatment of Metastatic Colorectal Cancer
6个月前
已完结
Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial
6个月前
已完结
皖公网安备34019202002308
